About Ikena Oncology
Ikena Oncology is a company based in Boston (United States) founded in 2016 by George Georgiou.. Ikena Oncology has raised $169 million across 3 funding rounds from investors including Fidelity Investments, TD Securities and Citadel. The company has 80 employees as of March 31, 2023. Ikena Oncology has completed 1 acquisition, including Pionyr Immuntherapeutics. Ikena Oncology offers products and services including Targeted Oncology Therapies. Ikena Oncology operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter Boston, United States
- Employees 80 as on 31 Mar, 2023
- Founders George Georgiou
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$169 M (USD)
in 3 rounds
-
Latest Funding Round
$42.57 M (USD), Post-IPO
Aug 19, 2023
-
Investors
Fidelity Investments
& 11 more
-
Employee Count
80
as on Mar 31, 2023
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Ikena Oncology
Ikena Oncology offers a comprehensive portfolio of products and services, including Targeted Oncology Therapies. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Develops biomarker-driven treatments for cancer growth and resistance
Unlock access to complete
Funding Insights of Ikena Oncology
Ikena Oncology has successfully raised a total of $169M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $42.57 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Post-IPO — $42.6M
-
First Round
First Round
(14 Dec 2017)
- Investors Count 12
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2023 | Amount | Post-IPO - Ikena Oncology | Valuation |
investors |
|
| Jan, 2021 | Amount | Series B - Ikena Oncology | Valuation | Omega Funds | |
| Dec, 2017 | Amount | Series A - Ikena Oncology | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Ikena Oncology
Ikena Oncology has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include Fidelity Investments, TD Securities and Citadel. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm
|
Founded Year | Domain | Location | |
|
Long-term private equity investments in transformational opportunities are pursued.
|
Founded Year | Domain | Location | |
|
Multiple investment strategies are pursued by this hedge fund.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Ikena Oncology
Ikena Oncology has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pionyr Immuntherapeutics. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Cancer immunotherapies that target the tumour microenvironment to enhance the body’s antitumour immunity
|
2015 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - Ikena Oncology
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Ikena Oncology Comparisons
Competitors of Ikena Oncology
Ikena Oncology operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Ikena Oncology
Frequently Asked Questions about Ikena Oncology
When was Ikena Oncology founded?
Ikena Oncology was founded in 2016 and raised its 1st funding round 1 year after it was founded.
Where is Ikena Oncology located?
Ikena Oncology is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Ikena Oncology a funded company?
Ikena Oncology is a funded company, having raised a total of $169M across 3 funding rounds to date. The company's 1st funding round was a Series A of $49M, raised on Dec 14, 2017.
How many employees does Ikena Oncology have?
As of Mar 31, 2023, the latest employee count at Ikena Oncology is 80.
What does Ikena Oncology do?
Developer of biomarker-based therapies for treating cancer. The lead product candidate IK-007 is currently in clinical development for the treatment of microsatellite stable colorectal cancer and PD-1L1 refractory non-small cell lung cancer. The other drug candidates include IK-930 for Hippo-mutated cancers and solid tumors, IK-1751 for bladder cancer, and others.
Who are the top competitors of Ikena Oncology?
Ikena Oncology's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Ikena Oncology offer?
Ikena Oncology offers Targeted Oncology Therapies.
How many acquisitions has Ikena Oncology made?
Ikena Oncology has made 1 acquisition, including Pionyr Immuntherapeutics.
Who are Ikena Oncology's investors?
Ikena Oncology has 12 investors. Key investors include Fidelity Investments, TD Securities, Citadel, Orbimed, and Farallon Capital Management.